BioWorld

July 17, 2009

View Archived Issues

The 'Rights' Stuff: Offering Gains Pharmacyclics $24M

Rebounding from its 2007 troubles with lung cancer drug Xcytrin, Pharmacyclics Inc. has emerged with a retooled management team, a multiproduct pipeline and a rather unusual - at least for biotech - money-raising strategy. (BioWorld Today) Read More

Amgen to Face Bundling Hits; CMS Rule Tolerable for Others

Read More

Tysabri Sales Stay Strong in a Good Biogen Quarter

Read More

NewCo News: AngioChem Crossing Barriers in Efforts to Heal the Brain

Read More

BDSI's Cancer Pain Film Onsolis Wins FDA OK

Read More

Clinic Roundup

Read More

Appointments And Advancements

Read More

Other News To Note

Read More